847375-33-1

Basic information

• Product Name: 3-Pyridineacetic acid, 5-broMo-, ethyl ester
• Synonyms: 3-Pyridineacetic acid, 5-broMo-, ethyl ester;Ethyl 2-(5-broMopyridin-3-yl)acetate
• CAS NO: 847375-33-1
• Molecular Formula: C₉H₁₀BrNO₂
• Molecular Weight: 244.0852
• Mol File: 847375-33-1.mol
• Article Data: 10

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 3-Pyridineacetic acid, 5-broMo-, ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Pyridineacetic acid, 5-broMo-, ethyl ester(847375-33-1)
• EPA Substance Registry System: 3-Pyridineacetic acid, 5-broMo-, ethyl ester(847375-33-1)

Safety Data

• Hazardous Substances Data: 847375-33-1(Hazardous Substances Data)

Usage

General Description

3-Pyridineacetic acid, 5-broMo-, ethyl ester is a chemical compound that belongs to the class of pyridine derivatives. It is an ethyl ester derivative of 3-pyridineacetic acid with a bromine atom located at the 5th position of the pyridine ring. 3-Pyridineacetic acid, 5-broMo-, ethyl ester is used in organic synthesis and medicinal chemistry as a building block for the preparation of various pharmaceuticals and bioactive compounds. Its chemical structure and properties make it useful for research and development in the pharmaceutical industry.

Upstream product

• 1071-46-1 hydrogen ethyl malonate 
• 39741-46-3 3-bromo-5-(chloromethyl)-pyridine hydrochloride 
• 64-17-5 ethanol 
• 39891-08-2 (5-bromo-pyridin-3-yl)-acetonitrile 
• 37669-64-0 (5-bromopyridin-3-yl)methanol 
• 39891-12-8 5-bromo-3-pyridineacetic acid 

Downstream Products

• 1219935-45-1 (5-{2-[(N-Benzyl-N-cyclopropanecarbonyl-amino)-methyl]-4-cyano-phenyl}-pyridin-3-yl)-acetic acid 
• 1219935-94-0 (5-{2-[(benzyl-cyclopropanecarbonyl-amino)-methyl]-4-cyano-phenyl}-pyridin-3-yl)-acetic acid ethyl ester 

Relevant articles and documents

POLYCYCLIC COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES

The present disclosure relates to bifunctional compounds, ULM— L—PTM, which find utility as modulators of Rapidly Accelerated Fibrosarcoma (RAF, such as c-RAF, A- RAF and/or B-RAF; the target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a Von Hippel-Lindau, cereblon, Inhibitors of Apotosis Proteins or mouse double-minute homolog 2 ligand which binds to the respective E3 ubiquitin ligase and on the other end a moiety which binds the target protein RAF, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein, or the constitutive activation of the target protein, are treated or prevented with compounds and compositions of the present disclosure.

Discovery of Molidustat (BAY 85-3934): A Small-Molecule Oral HIF-Prolyl Hydroxylase (HIF-PH) Inhibitor for the Treatment of Renal Anemia

Small-molecule inhibitors of hypoxia-inducible factor prolyl hydroxylases (HIF-PHs) are currently under clinical development as novel treatment options for chronic kidney disease (CKD) associated anemia. Inhibition of HIF-PH mimics hypoxia and leads to increased erythropoietin (EPO) expression and subsequently increased erythropoiesis. Herein we describe the discovery, synthesis, structure–activity relationship (SAR), and proposed binding mode of novel 2,4-diheteroaryl-1,2-dihydro-3H-pyrazol-3-ones as orally bioavailable HIF-PH inhibitors for the treatment of anemia. High-throughput screening of our corporate compound library identified BAY-908 as a promising hit. The lead optimization program then resulted in the identification of molidustat (BAY 85-3934), a novel small-molecule oral HIF-PH inhibitor. Molidustat is currently being investigated in clinical phase III trials as molidustat sodium for the treatment of anemia in patients with CKD.

Charting the Chemical Reactivity Space of 2,3-Substituted Furo[2,3-b]pyridines Synthesized via the Heterocyclization of Pyridine-N-oxide Derivatives

A concise strategy for the synthesis of 2,3-substituted furo[2,3-b]pyridines is described. Mild, metal-free conditions were successfully applied to produce a range of 2-(alkyl or aryl)-3-ethylcarboxylate-furo[2,3-b]pyridines in yields of 50-91%. Then, the chemical reactivity of this heterocyclic framework was explored to develop straightforward methods for its functionalization. The pyridine moiety reactivity was successfully explored by C-H amination and borylation reactions, although C-H fluorination and radical C-H arylation processes were not as efficient. In addition, while the furopyridine core proved stable under basic conditions, the ring-opening reaction of the furan moiety with hydrazine generated a valuable new pyridine-dihydropyrazolone scaffold.